fingolimod hydrochloride has been researched along with Pulmonary Fibrosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanchet, MR; Bossé, Y; Dion, G; Gendron, DR; Huppé, CA; Lecours, PB; Lemay, AM; Marsolais, D; Perreault-Vallières, V | 1 |
| Lv, L; Qian, J; Ye, S; Ye, Y; Zhu, C | 1 |
2 other study(ies) available for fingolimod hydrochloride and Pulmonary Fibrosis
| Article | Year |
|---|---|
FTY720 promotes pulmonary fibrosis when administered during the remodelling phase following a bleomycin-induced lung injury.
Topics: Animals; Bleomycin; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; Inflammation; Lung Injury; Male; Mice; Mice, Inbred C57BL; Neutrophils; Pulmonary Fibrosis; Time Factors | 2017 |
FTY720 attenuates paraquat-induced lung injury in mice.
Topics: Actins; Acute Lung Injury; Animals; Body Weight; Bronchoalveolar Lavage Fluid; Collagen Type I; Collagen Type III; Disease Models, Animal; Fingolimod Hydrochloride; Interleukin-1beta; Interleukin-6; Lung; Lung Injury; Mice; Mice, Inbred C57BL; Paraquat; Propylene Glycols; Pulmonary Edema; Pulmonary Fibrosis; Sphingosine; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2014 |